Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Evusheld

EISAI

Eisai’s thyroid cancer drug Lenvima nears EU approval

Positive recommendation by the CHMP could see the orphan drug used in Europe within three months

UK Life Sciences Strategy - one year on

AstraZeneca joins Genomics England consortium

Combines with other pharma firms such as Illumina to utilise genetic data to create new medicines

- PMLiVE

Final NICE ‘no’ for Celgene’s Imnovid

England’s pricing watchdog says multiple myeloma drug is just too expensive for the NHS

- PMLiVE

AZ links with Harvard for diabetes research

Firm extends ties with the highly respected academic institution in hope of finding innovative leads

Seismic shifts: Hepatitis C and payers

How hep C is causing paradigm changes in payer behaviour

- PMLiVE

AZ and Daiichi Sankyo sign Movantik marketing deal

Two firms have agreed the deal for the new constipation pill

- PMLiVE

AstraZeneca scores in final lung disease drug trials

The firm hopes it LAMA/LABA drug can take a big chunk from the $14bn COPD market

- PMLiVE

AstraZeneca’s heart drug impresses, but bleeding risks a concern

Firm still hopes the new Brilinta data can help the medicine be a blockbuster

National Institute for Health and Care Excellence NICE logo

NICE system ‘slowing market access to cancer meds’

Two new reports show that UK access to new treatments and survival rates among lowest in Europe

- PMLiVE

AstraZeneca bullish on diabetes franchise fortunes

Other big pharma firms face a difficult 2015, but AZ is confident it won't

- PMLiVE

NICE gives nod to blood cancer drug Gazyvaro

Roche’s leukaemia drug to be used in combination with chemotherapy

- PMLiVE

Cancer Drugs Fund cull ‘won’t save NHS money’

New survey also finds that oncologists believe the cuts will ‘worsen patient outcomes’

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links